Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines

Overview

Journal Vaccines (Basel)

Date 2015 Sep 8

PMID 26343192

Citations 102

Authors

Saranya Sridhar

Karl A Brokstad

Rebecca J Cox

Affiliations

Soon will be listed here.

Abstract

Influenza is a major respiratory pathogen causing annual outbreaks and occasional pandemics. Influenza vaccination is the major method of prophylaxis. Currently annual influenza vaccination is recommended for groups at high risk of complications from influenza infection such as pregnant women, young children, people with underlying disease and the elderly, along with occupational groups such a healthcare workers and farm workers. There are two main types of vaccines available: the parenteral inactivated influenza vaccine and the intranasal live attenuated influenza vaccine. The inactivated vaccines are licensed from 6 months of age and have been used for more than 50 years with a good safety profile. Inactivated vaccines are standardized according to the presence of the viral major surface glycoprotein hemagglutinin and protection is mediated by the induction of vaccine strain specific antibody responses. In contrast, the live attenuated vaccines are licensed in Europe for children from 2-17 years of age and provide a multifaceted immune response with local and systemic antibody and T cell responses but with no clear correlate of protection. Here we discuss the immunological immune responses elicited by the two vaccines and discuss future work to better define correlates of protection.

Citing Articles

Integrative Mapping of Pre-existing Immune Landscapes for Vaccine Response Prediction.

Hao S, Tomic I, Lindsey B, Jagne Y, Hoschler K, Meijer A bioRxiv. 2025; .

PMID: 39896552 PMC: 11785181. DOI: 10.1101/2025.01.22.634302.

A Study on the Induction of Multi-Type Immune Responses in Mice via an mRNA Vaccine Based on Hemagglutinin and Neuraminidase Antigen.

Liu M, Liu Y, Song S, Qiao Q, Liu J, Xie Y Vaccines (Basel). 2025; 13(1).

PMID: 39852870 PMC: 11769188. DOI: 10.3390/vaccines13010091.

Truncated NS1 Influenza A Virus Induces a Robust Antigen-Specific Tissue-Resident T-Cell Response and Promotes Inducible Bronchus-Associated Lymphoid Tissue Formation in Mice.

Shurygina A, Shuklina M, Ozhereleva O, Romanovskaya-Romanko E, Kovaleva S, Egorov A Vaccines (Basel). 2025; 13(1).

PMID: 39852837 PMC: 11769193. DOI: 10.3390/vaccines13010058.

Approaches to Enhance the Potency of Vaccines in Chickens.

Bodman-Harris O, Rollier C, Iqbal M Vaccines (Basel). 2025; 12(12.

PMID: 39771998 PMC: 11680195. DOI: 10.3390/vaccines12121337.

Next-generation vaccines for influenza B virus: advancements and challenges.

Ashraf M, Asif Raza M, Imran A, Amjad M Arch Virol. 2025; 170(2):25.

PMID: 39762648 DOI: 10.1007/s00705-024-06210-4.

References

Clark A, POTTER C, Jennings R, Nicholl J, Langrick A, Schild G . A comparison of live and inactivated influenza A (H1N1) virus vaccines. 1. Short-term immunity. J Hyg (Lond). 1983; 90(3):351-9. PMC: 2134273. DOI: 10.1017/s0022172400028989. View

Belshe R, Edwards K, Vesikari T, Black S, Walker R, Hultquist M . Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007; 356(7):685-96. DOI: 10.1056/NEJMoa065368. View

Kohlmeier J, Cookenham T, Miller S, Roberts A, Christensen J, Thomsen A . CXCR3 directs antigen-specific effector CD4+ T cell migration to the lung during parainfluenza virus infection. J Immunol. 2009; 183(7):4378-84. PMC: 2757292. DOI: 10.4049/jimmunol.0902022. View

Belshe R, Lee M, Walker R, Stoddard J, Mendelman P . Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Expert Rev Vaccines. 2004; 3(6):643-54. DOI: 10.1586/14760584.3.6.643. View

Cox R, Haaheim L . The effect of age and natural priming on the IgG and IgA subclass responses after parenteral influenza vaccination. J Infect Dis. 1999; 180(4):1356-60. DOI: 10.1086/315003. View

Turner D, Farber D . Mucosal resident memory CD4 T cells in protection and immunopathology. Front Immunol. 2014; 5:331. PMC: 4094908. DOI: 10.3389/fimmu.2014.00331. View

Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, Della Cioppa G . Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J. 2011; 30(12):1081-5. DOI: 10.1097/INF.0b013e3182367662. View

Strutt T, McKinstry K, Marshall N, Vong A, Dutton R, Swain S . Multipronged CD4(+) T-cell effector and memory responses cooperate to provide potent immunity against respiratory virus. Immunol Rev. 2013; 255(1):149-64. PMC: 4206082. DOI: 10.1111/imr.12088. View

Wilkinson T, Li C, Chui C, Huang A, Perkins M, Liebner J . Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med. 2012; 18(2):274-80. DOI: 10.1038/nm.2612. View

10.

Nakaya H, Wrammert J, Lee E, Racioppi L, Marie-Kunze S, Nicholas Haining W . Systems biology of vaccination for seasonal influenza in humans. Nat Immunol. 2011; 12(8):786-95. PMC: 3140559. DOI: 10.1038/ni.2067. View

11.

Mohn K, Bredholt G, Brokstad K, Pathirana R, Aarstad H, Tondel C . Longevity of B-cell and T-cell responses after live attenuated influenza vaccination in children. J Infect Dis. 2014; 211(10):1541-9. PMC: 4407761. DOI: 10.1093/infdis/jiu654. View

12.

Couch R, KASEL J, Gerin J, SCHULMAN J, KILBOURNE E . Induction of partial immunity to influenza by a neuraminidase-specific vaccine. J Infect Dis. 1974; 129(4):411-20. DOI: 10.1093/infdis/129.4.411. View

13.

Jiang N, He J, Weinstein J, Penland L, Sasaki S, He X . Lineage structure of the human antibody repertoire in response to influenza vaccination. Sci Transl Med. 2013; 5(171):171ra19. PMC: 3699344. DOI: 10.1126/scitranslmed.3004794. View

14.

Ramos E, Mitcham J, Koller T, Bonavia A, Usner D, Balaratnam G . Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza. J Infect Dis. 2014; 211(7):1038-44. DOI: 10.1093/infdis/jiu539. View

15.

Osterholm M, Kelley N, Sommer A, Belongia E . Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2011; 12(1):36-44. DOI: 10.1016/S1473-3099(11)70295-X. View

16.

Eriksson J, Cox R, Szyszko E, Davidsson A, Brokstad K . Local and systemic cytokine and chemokine responses after parenteral influenza vaccination. Influenza Other Respir Viruses. 2009; 1(4):139-46. PMC: 4634537. DOI: 10.1111/j.1750-2659.2007.00019.x. View

17.

Brokstad K, Cox R, Olofsson J, Jonsson R, Haaheim L . Parenteral influenza vaccination induces a rapid systemic and local immune response. J Infect Dis. 1995; 171(1):198-203. DOI: 10.1093/infdis/171.1.198. View

18.

Powers D, Smith G, Anderson E, Kennedy D, Hackett C, Wilkinson B . Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. J Infect Dis. 1995; 171(6):1595-9. DOI: 10.1093/infdis/171.6.1595. View

19.

Moser B, Schaerli P, Loetscher P . CXCR5(+) T cells: follicular homing takes center stage in T-helper-cell responses. Trends Immunol. 2002; 23(5):250-4. DOI: 10.1016/s1471-4906(02)02218-4. View

20.

McMichael A, Gotch F, Dongworth D, Clark A, POTTER C . Declining T-cell immunity to influenza, 1977-82. Lancet. 1983; 2(8353):762-4. DOI: 10.1016/s0140-6736(83)92297-3. View